Fostamatinib for Persistent/Chronic Adult Immune Thrombocytopenia
Authors:
- 2 October 2017
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (1) , 9-25
Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by phagocytosis and destruction of autoantibody-coated platelets via spleen tyrosine kinase (Syk)-mediated signal transduction in macrophages. Effectiveness of existing therapies varies, and even leading treatments (e.g., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic ITP. Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chronic adult ITP. Fostamatinib inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis. Promising findings have been described in several autoimmune diseases, including rheumatoid arthritis, and sustained responses with manageable adverse events observed with ongoing treatment in patients with heavily treated chronic ITP. Fostamatinib represents an active therapy targeting a previously unexplored mechanism of ITP pathogen...Keywords
Funding Information
- Amgen
- GlaxoSmithKline
- Novartis
- Argenx
- Dova Pharmaceuticals
- E Lee
- Rigel Pharmaceuticals
- Baxter
This publication has 67 references indexed in Scilit:
- Increased Number of Tc17 and Correlation with Th17 Cells in Patients with Immune ThrombocytopeniaPLOS ONE, 2011
- Piecing Together the Humoral and Cellular Mechanisms of Immune ThrombocytopeniaSeminars in Thrombosis and Hemostasis, 2011
- Therapeutic Targeting of Syk in Autoimmune DiabetesThe Journal of Immunology, 2010
- Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone miceArthritis & Rheumatism, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseHaematologica, 2010
- Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpuraHaematologica, 2009
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic targetBlood, 2009
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003